<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05055687</url>
  </required_header>
  <id_info>
    <org_study_id>FL058-I-02</org_study_id>
    <nct_id>NCT05055687</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous FL058 Administered in Healthy Subjects(SAD/MAD)</brief_title>
  <official_title>A Randomized, Double-Blind, Single- Multiple Dose, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of FL058 for Injection in Healthy Chinese Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qilu Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qilu Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety,tolerability and pharmacokinetics of single-multiple intravenous doses&#xD;
      of FL058 in healthy Chinese subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is divided into two parts: A and B.Part A discusses the safety and tolerability of&#xD;
      IV FL058 single ascending dose (SAD) in two cohorts. Part B discusses the safety and&#xD;
      tolerability of intravenous injection of FL058 in multiple dose (MAD) in three cohorts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 5, 2020</start_date>
  <completion_date type="Actual">July 27, 2020</completion_date>
  <primary_completion_date type="Actual">July 27, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A:Number of patients with adverse events [Safety and Tolerability]</measure>
    <time_frame>Day 1 to Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B:Number of patients with adverse events [Safety and Tolerability]</measure>
    <time_frame>Day 1 to Day 12</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part A：FL058</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a single ascending dose (SAD) of intravenous (IV) FL058(2500mg~3000mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A：Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>FL058 Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B：FL058</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a multiple ascending dose (MAD) of intravenous (IV) FL058(500mg~2000mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B：Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>FL058 Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FL058</intervention_name>
    <description>2500mg、3000mg</description>
    <arm_group_label>Part A：FL058</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>empty bottle</description>
    <arm_group_label>Part A：Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FL058</intervention_name>
    <description>500mg、1000mg、2000mg</description>
    <arm_group_label>Part B：FL058</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>empty bottle</description>
    <arm_group_label>Part B：Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adults aged between 18 and 45 years (inclusive).&#xD;
&#xD;
          2. Body mass index (BMI) ranges from 19 to 26 kg/m2 (inclusive), and the body weight is&#xD;
             ≥50kg.&#xD;
&#xD;
          3. Good general health as determined by the Investigator based on medical history,&#xD;
             physical examination, vital signs, 12-lead ECG and clinical laboratory tests.&#xD;
&#xD;
          4. Provide voluntary written informed consent prior to any study procedures and are&#xD;
             willing and able to comply with the prescribed treatment protocol and evaluations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Concurrent or history of clinically significant cardiovascular, hepatic, renal,&#xD;
             endocrine, gastrointestinal, respiratory, psychiatric, neurologic and/or hematological&#xD;
             disorders.&#xD;
&#xD;
          2. Positive screen result for HBsAg, HCV-Ab, or HIV-Ab at screening.&#xD;
&#xD;
          3. History of clinically significant food or drug allergy.&#xD;
&#xD;
          4. A QT interval corrected using Fridericia's formula &gt;450 msec.&#xD;
&#xD;
          5. eGFR&lt;90mL/min/1.73m2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Huashan Hospital affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 8, 2021</study_first_submitted>
  <study_first_submitted_qc>September 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

